Abstract
BackgroundSerous epithelial ovarian tumors can be subdivided into benign (BOV), low malignant potential (LMP) or borderline and invasive (TOV) tumors. Although the molecular characteristics of serous BOV, LMP and low grade (LG) TOV tumors has been initiated, definitive immunohistochemical markers to distinguish between these tumor types have not been defined.MethodsIn the present study, we used a tissue array composed of 27 BOVs, 78 LMPs and 23 LG TOVs to evaluate the protein expression of a subset of selected candidates identified in our previous studies (Ape1, Set, Ran, Ccne1 and Trail) or known to be implicated in epithelial ovarian cancer disease (p21, Ccnb1, Ckd1).ResultsStatistically significant difference in protein expression was observed for Ccnb1 when BOV tumors were compared to LMP tumors (p = 0.003). When BOV were compared to LG TOV tumors, Trail was significantly expressed at a higher level in malignant tumors (p = 0.01). Expression of p21 was significantly lower in LG tumors when compared with either BOVs (p = 0.03) or LMPs (p = 0.001). We also observed that expression of p21 was higher in LMP tumors with no (p = 0.02) or non-invasive (p = 0.01) implants compared to the LMP associated with invasive implants.ConclusionThis study represents an extensive analyse of the benign and highly differentiated ovarian disease from an immunohistochemical perspective.
Highlights
Serous epithelial ovarian tumors can be subdivided into benign (BOV), low malignant potential (LMP) or borderline and invasive (TOV) tumors
Significant differences in protein expression were observed for Ccnb1 when Benign ovarian tumor (BOV) were compared to LMP tumors
When BOV were compared to low grade (LG) Malignant ovarian tumor (TOV) tumors, Trail was significantly overexpressed in the malignant tumor (p = 0.01) (Table 2)
Summary
Serous epithelial ovarian tumors can be subdivided into benign (BOV), low malignant potential (LMP) or borderline and invasive (TOV) tumors. Tumors of the ovary represent a large, heterogeneous and complex group of neoplasms. The majority of these tumors are derived from ovarian surface epithelial cells, from epithelial inclusion cysts confined in the stroma or from the epithelium of the fallopian tube [1,2]. Serous tumors can be subdivided into benign (BOV), borderline or low malignant potential (LMP) and invasive (TOV) tumors. LMP tumors are distinguished from their benign counterpart by the complexity of their architecture and the presence of epithelial budding. LMP tumor cells exhibit some nuclear atypia and show a higher mitotic activity when compared to BOV [reviewed in [5,6,7,8,9]]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
